An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients

• Status: Completed
• Trial end date: 2013-05-02
• Target enrollment: 0
• Participant gender: All

Summary

This is an open-label extension study to assess the long-term safety and tolerability of pimavanserin (ACP-103) in subjects with Parkinson's Disease Psychosis (PDP).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: ACADIA Pharmaceuticals Inc.
• Treatments: Pimavanserin

Criteria

Inclusion Criteria-

• Patients of any age, male or female with a clinical diagnosis of idiopathic Parkinson's disease, who participated in a previous (Phase II) clinical trial that evaluated pimavanserin

• Patients who may, in the opinion of the treating physician, benefit from continued therapy with pimavanserin

• Patient is willing and able to provide consent

Exclusion Criteria-

• Female patient of childbearing potential

• Patient has a clinically significant concurrent medical illness

• Patient is judged by the treating physician to be inappropriate for the study.